Posted inBiotechnology
How Our Diet Influences Health and Gene Expression
Fiber has long been heralded as a cornerstone of a nutritious diet, contributing significantly to overall health and wellness. Despite…
Posted inBiotechnology
New Lung Cancer Test Outperforms Traditional Methods in Predicting Early-Stage Survival
A groundbreaking development in cancer diagnostics has emerged from the collaborative research conducted at the Francis Crick Institute and the…
Posted inBiotechnology
Breakthrough in Cold Quantum Refrigeration Sets the Stage for Reliable Quantum Computing
The race to enhance quantum computing technology has taken a significant turn with the development of an innovative quantum refrigerator…
Posted inBiotechnology
New Standards Introduced for Accurate Emission Testing of Motorcycles, Mopeds, and Quads
In the wake of the 2015 emissions scandal that shook the automotive industry, the conversation around realistic vehicle emissions testing…
Posted inBiotechnology
Climb Bio ascends from Eliem legacy with $9M upfront deal for preclinical IgA antibody
Eliem Therapeutics is continuing its transformation into an immune-mediated disease company by paying $9 million to license a Chinese biotech’s…
Posted inBiotechnology
JPM25, Day 1: GSK’s billion-dollar bet, Bayer’s trial first, and more
The J.P. Morgan Healthcare Conference in San Francisco is back for 2025 and here at Fierce Biotech, we’re going to…
Posted inBiotechnology
Bayer makes hot flash splash, hitting phase 3 breast cancer goal to steal march on Astellas
Bayer’s hot flash drug candidate has hit the mark in a phase 3 breast cancer trial, potentially positioning the German drugmaker…
Posted inBiotechnology
Astellas calls it quits on early-stage lymphoma CAR-T following pipeline review
On Astellas Pharma’s mission to develop new cell therapies in cancers and other diseases, not all candidates are destined to…
Posted inBiotechnology
Unveiling Hidden Wrinkles in Spacecraft Membranes Using a Single Camera
Deep in the realms of aerospace engineering, a groundbreaking study is taking shape, one that could potentially redefine how we…
Posted inBiotechnology
MaaT’s phase 3 GvHD trial hits goal, teeing up microbiome filing if cash crunch clears
A phase 3 trial of MaaT Pharma’s graft-versus-host disease (GvHD) drug candidate has hit its primary endpoint, positioning the biotech to…